Selective inhibition of histone deacetylase 8 improves vascular hypertrophy, relaxation, and inflammation in angiotensin II hypertensive mice

키워드

참고문헌 (58)

1. Suri MF, "Hypertensive retinopathy and risk of cardiovascular diseases in a national cohort", J Vasc Interv Neurol, 1, pp.75~78 (2008)
2. Wong TY, "Hypertensive retinopathy signs as risk indicators of cardiovascular morbidity and mortality", Br Med Bull, 73-74, pp.57~70 (2005)
3. Bakris G, "Review of blood pressure control rates and outcomes", J Am Soc Hypertens, 8, pp.127~141 (2014)
4. Boos CJ, "Is hypertension an inflammatory process?", Curr Pharm Des, 12, pp.1623~1635 (2006)
5. Savoia C, "Inflammation in hypertension", Curr Opin Nephrol Hypertens, 15, pp.152~158 (2006)
6. Cheng ZJ, "Angiotensin II and vascular inflammation", Med Sci Monit, 11, pp.RA194~205 (2005)
7. Pueyo ME, "Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress", Arterioscler Thromb Vasc Biol, 20, pp.645~651 (2000)
8. Pastore L, "Angiotensin II stimulates intercellular adhesion molecule-1(ICAM-1)expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo", Circulation, 100, pp.1646~1652 (1999)
9. Shalia KK, "Circulating levels of cell adhesion molecules in hypertension", Indian J Clin Biochem, 24, pp.388~397 (2009)
10. Miller MA, "Cellular adhesion molecules and blood pressure : interaction with sex in a multi-ethnic population", J Hypertens, 22, pp.705~711 (2004)
11. DeSouza CA, "Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension", Am J Hypertens, 10, pp.1335~1341 (1997)
12. Mu W, "Expression of vascular cell adhesion molecule-1 in the aortic tissues of atherosclerotic patients and the associated clinical implications", Exp Ther Med, 10, pp.423~428 (2015)
13. Kuroda YT, "Vascular cell adhesion molecule-1 as a biochemical marker of left ventricular mass in the patients with hypertension", Am J Hypertens, 14, pp.868~872 (2001)
14. Dandona P, "Angiotensin II and inflammation : the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade", J Hum Hypertens, 21, pp.20~27 (2007)
15. Goulopoulou S, "Symphony of vascular contraction : how smooth muscle cells lose harmony to signal increased vascular resistance in hypertension", Hypertension, 63, pp.e33~9 (2014)
16. Rembold CM, "Regulation of contraction and relaxation in arterial smooth muscle", Hypertension, 20, pp.129~137 (1992)
17. Yoon S, "HDAC and HDAC inhibitor : from Cancer to cardiovascular diseases", Chonnam Med J, 52(1), pp.11~ (2016)
18. McKinsey TA, "Therapeutic potential for HDAC inhibitors in the heart", Annu Rev Pharmacol Toxicol, 52, pp.303~319 (2012)
19. Kee HJ, "Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding", Circulation, 113, pp.51~59 (2006)
20. Cao DJ, "Histone deacetylase(HDAC)inhibitors attenuate cardiac hypertrophy by suppressing autophagy", Proc Natl Acad Sci U S A, 108, pp.4123~4128 (2011)
21. Cardinale JP, "HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats", Hypertension, 56, pp.437~444 (2010)
22. Lee HA, "Histone deacetylase inhibition attenuates transcriptional activity of mineralocorticoid receptor through its acetylation and prevents development of hypertension", Circ Res, 112, pp.1004~1012 (2013)
23. Kee HJ, "HDAC inhibition suppresses cardiac hypertrophy and fibrosis in DOCA-salt hypertensive rats via regulation of HDAC6", HDAC8 enzyme activity, 2013, pp.37, 229~239
24. Kim GR, "Histone deacetylase and GATA-binding factor 6 regulate arterial remodeling in angiotensin IIinduced hypertension", J Hypertens, 34, pp.2206~2219 (2016)
25. Ingham OJ, "Development of a potent and selective HDAC8 inhibitor", ACS Med Chem Lett, 7, pp.929~932 (2016)
26. Balasubramanian S, "A novel histone deacetylase 8(HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas", Leukemia, 22, pp.1026~1034 (2008)
27. Zhang Y, "Vascular hypertrophy in angiotensin II-induced hypertension is mediated by vascular smooth muscle cell-derived H2O2", Hypertension, 46, pp.732~737 (2005)
28. Fish JE, "Endothelial nitric oxide synthase : insight into cellspecific gene regulation in the vascular endothelium", Cell Mol Life Sci, 63, pp.144~162 (2006)
29. Harrison DG, "Inflammation, immunity, and hypertension", Hypertension, 57, pp.132~140 (2011)
30. Dinh QN, "Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension", Biomed Res Int, 2014, pp.406960~ (2014)
31. Mehaffey E, "Tumor necrosis factor-alpha, kidney function, and hypertension", Am J Physiol Renal Physiol, 313, pp.F1005~ (2017)[DOI]
32. Ramseyer VD, "Tumor necrosis factor-alpha : regulation of renal function and blood pressure", Am J Physiol Renal Physiol, 304, pp.F1231~42 (2013)
33. Krishnan SM, "IL-1beta and IL-18: inflammatory markers or mediators of hypertension?", Br J Pharmacol, 171, pp.5589~5602 (2014)
34. Chen XL, "Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells", Circ Res, 83, pp.952~959 (1998)
35. Oliveira-Paula GH, "Inducible nitric oxide synthase as a possible target in hypertension", Curr Drug Targets, 15, pp.164~174 (2014)
36. Chamarthi B, "Inflammation and hypertension : the interplay of interleukin-6, dietary sodium, and the renin-angiotensin system in humans", Am J Hypertens, 24, pp.1143~1148 (2011)
37. Hernandez J, "Angiotensin II stimulates cyclooxygenase-2 mRNA expression in renal tissue from rats with kidney failure", Am J Physiol Ren Physiol, 282, pp.F592~8 (2002)
38. Krieglstein CF, "Adhesion molecules and their role in vascular disease", Am J Hypertens, 14, pp.44~ (2001)[DOI]
39. Videm V, "Soluble ICAM-1 and VCAM-1 as markers of endothelial activation", Scand J Immunol, 67, pp.523~531 (2008)
40. Cook-Mills JM, "Vascular cell adhesion molecule-1 expression and signaling during disease : regulation by reactive oxygen species and antioxidants", Antioxid Redox Signal, 15, pp.1607~1638 (2011)
41. Nguyen Dinh Cat A, "Angiotensin II, NADPH oxidase, and redox signaling in the vasculature", Antioxid Redox Signal, 19, pp.1110~1120 (2013)
42. Choi J, "Role of the histone deacetylase inhibitor valproic acid in high-fat diet-induced hypertension via inhibition of HDAC1", angiotensin II axis, 2017, pp.41, 1702~1709
43. Lee HA, "Histone deacetylase inhibition ameliorates hypertension and hyperglycemia in a model of Cushing's syndrome", Am J Physiol Endocrinol Metab, 314, pp.E39~52 (2018)
44. Crowley SD, "Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney", Proc Natl Acad Sci U S A, 103, pp.17985~17990 (2006)
45. Siragy HM, "Mechanism of action of angiotensin-receptor blocking agents", Curr Hypertens Rep, 1, pp.289~295 (1999)
46. Li H, "Calmodulin kinase II is required for angiotensin II-mediated vascular smooth muscle hypertrophy", Am J Physiol Heart Circ Physiol, 298, pp.H688~98 (2010)
47. Humbert PO, "E2f3is critical for normal cellular proliferation", Genes Dev, 14, pp.690~703 (2000)
48. 이은조, "Histone deacetylase inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats", The Korean Journal of Physiology & Pharmacology, 20(5), pp.477~485 (2016), 대한약리학회
49. Zheng C, "Histone deacetylase inhibitors relax mouse aorta partly through their inhibitory action on L-type ca(2+)channels", J Pharmacol Exp Ther, 363, pp.211~220 (2017)
50. 강건, "Trichostatin A Modulates Angiotensin II-induced Vasoconstriction and Blood Pressure Via Inhibition of p66shc Activation", The Korean Journal of Physiology & Pharmacology, 19(5), pp.467~472 (2015), 대한약리학회
51. Usui T, "HDAC4 mediates development of hypertension via vascular inflammation in spontaneous hypertensive rats", Am J Physiol Heart Circ Physiol, 302, pp.H1894~904 (2012)
52. Savoia C, "Vascular inflammation in hypertension and diabetes : molecular mechanisms and therapeutic interventions", Clin Sci(Lond), 112, pp.375~384 (2007)
53. Nomura S, "Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus", J Hum Hypertens, 16, pp.539~547 (2002)
54. De Ciuceis C, "Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colonystimulating factor-deficient mice : evidence for a role in inflammation in angiotensin-induced vascular injury", Arterioscler Thromb Vasc Biol, 25, pp.2106~2113 (2005)
55. Jin L, "Gallic acid reduces blood pressure and attenuates oxidative stress and cardiac hypertrophy in spontaneously hypertensive rats", Sci Rep, 7, pp.15607~ (2017)
56. Choi SY, "Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat", Biomed Pharmacother, 101, pp.145~154 (2018)
57. Manea SA, "Epigenetic regulation of vascular NADPH oxidase expression and reactive oxygen species production by histone deacetylase-dependent mechanisms in experimental diabetes", Redox Biol, 16, pp.332~343 (2018)
58. Chen F, "Inhibition of histone deacetylase reduces transcription of NADPH oxidases and ROS production and ameliorates pulmonary arterial hypertension", Free Radic Biol Med, 99, pp.167~178 (2016)

관련 논문AI추천